RMD Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
ResMed Inc (RMD) is not a strong buy for a beginner investor seeking long-term growth at this moment. While the company's financial performance is solid, the technical indicators and options data suggest a lack of immediate upward momentum. Additionally, the stock is currently trading in a pre-market downtrend, and there are no significant positive catalysts or trading signals to justify an immediate purchase.
The MACD histogram is negative and expanding, indicating bearish momentum. RSI is neutral at 29.07, and moving averages are converging, showing no clear trend. The stock is trading below key support levels, with S1 at 248.928 and S2 at 241.267, suggesting potential downside risk.
The company delivered strong Q2 financial results, with double-digit revenue and earnings growth. Analysts have raised price targets, with Citi setting a high target of $345 and maintaining a Buy rating.
Technical indicators show bearish momentum. No recent news or significant trading trends from hedge funds or insiders. Analysts have mixed ratings, with some maintaining Neutral or Hold positions due to concerns about future growth deceleration.
In Q2 2026, ResMed reported a 10.98% YoY revenue increase, 13.92% YoY net income growth, and a 14.53% YoY EPS increase. Gross margin improved to 60.93%, up 5.52% YoY, reflecting strong operational performance.
Analysts are mixed on the stock. While Citi and RBC Capital maintain Buy and Outperform ratings with high price targets, others like Piper Sandler and Baird remain Neutral, citing concerns about growth visibility and competitor expansion.
